Just a few months ago, Alteogen stood at the pinnacle of the KOSDAQ market, hailed as a platform technology powerhouse and a symbol of Korea’s biotech ambitions. Yet, as spring 2026 unfolds, the company’s reputation has taken a sharp turn, rattled by a combination of royalty rate disappointments, patent disputes, and shaken investor trust. The story of Alteogen’s recent struggles and its ongoing efforts to regain confidence offers a revealing look at the volatile world of biotech innovation and the high stakes of global pharmaceutical partnerships.
At the heart of the current turmoil is what industry watchers have dubbed the “royalty shock.” For years, market analysts and investors had pegged the expected royalty rate for Merck’s subcutaneous (SC) formulation of Keytruda—made possible by Alteogen’s ALT-B4 platform—at 4-5%. But when Merck publicly disclosed the actual figure, it came in at just 2%. According to ChosunBiz, this wasn’t merely a matter of numbers: “The premise underpinning the company’s valuation was shaken, and the impact was far greater than a simple ranking change.”
The fallout was immediate. Alteogen lost its spot as KOSDAQ’s market cap leader, and its share price tumbled. The disappointment was compounded by what many saw as a lack of transparency from Alteogen. Nowhere in its quarterly or annual reports had the company clarified the royalty structure, nor did it attempt to recalibrate market expectations ahead of the disclosure. As one industry observer told ChosunBiz, “The bigger problem was the company’s lack of communication during this process.”
Investor confidence took another hit when Halozyme, a rival biotech, filed a patent infringement lawsuit over the Keytruda SC formulation. While a UK court sided with Merck, the U.S. patent invalidity review (PGR) remains unresolved as of April 8, 2026, leaving a cloud of uncertainty hanging over Alteogen’s future royalty streams. The market, it seems, is less concerned with the outcome itself than with the ongoing uncertainty. As BizWatch noted, “Concerns have intensified as the royalty controversy and unresolved patent disputes have combined to amplify uncertainty.”
This uncertainty has not gone unnoticed among shareholders. The second largest shareholder, Hyung In-woo, openly opposed the reappointment of CFO Kim Hyang-yeon, citing a lack of faith in management. Traditional shareholder-friendly policies—like share buybacks, dividends, and bonus issues—were criticized as insufficient. The market’s message was clear: growth is important, but so is communication and tangible rewards for investors.
Yet, amid the turbulence, Alteogen’s financial fundamentals remain robust. The company posted record sales of 215.9 billion KRW and an operating profit of 106.9 billion KRW in 2025, according to BizWatch. These numbers, driven by the success of the Hybrozyme platform—which converts intravenous drugs to more convenient subcutaneous injections—are a testament to the company’s technological prowess. Indeed, Alteogen’s licensing portfolio with global giants like Merck (MSD), Daiichi Sankyo, and MedImmune has reached several billion dollars in value. The Merck deal alone, valued at $4.3 billion, covers the now-commercialized Keytruda SC formulation in the U.S. and Europe.
But in the world of biotech, past performance is only part of the story. As ChosunBiz pointed out, “The company’s current performance does not fully explain the ‘long-term growth story’ that the market expects. The value of a biotech company is determined more by its future revenue structure than by its current results.”
To address these concerns and show it’s not standing still, Alteogen has played some bold cards. In March 2026, it inked an exclusive license agreement with Biogen for the ALT-B4-based SC formulation technology—a deal that sent its stock price surging. Negotiations are underway with about ten other global pharmaceutical companies, and management hints that some of these talks could result in finalized contracts in the first half of the year. The platform’s flexibility—allowing multiple partners to work on similar targets—remains a key strength.
Still, the market remains cautious. As one industry source told ChosunBiz, “The key variable is the re-verification of the royalty structure. It’s not just about potential anymore; it’s about proof.” Investors want to see whether future licensing deals will secure higher royalty rates and if these agreements will translate into stable, long-term cash flows. The fate of numerous material transfer agreements (MTAs) hangs in the balance, and their conversion into meaningful revenue could yet shift market sentiment.
Beyond financials and contracts, Alteogen is also working to rebuild trust through governance and sustainability initiatives. On April 8, 2026, the company declared the year as its “first year of ESG management,” rolling out a comprehensive sustainability management system in line with global standards. According to Sejong Economic News, Alteogen established an ESG committee and dedicated teams, launched the “Alteogen Blue Action” campaign for biodiversity, and implemented science-based carbon neutrality targets. It also completed governance reforms, forming an audit committee with a majority of outside directors and planning to publish a sustainability report by year’s end.
CEO Jeon Tae-yeon emphasized the importance of these moves: “ESG is not a choice but a requirement in the global market, especially in the bio industry where it is directly linked to partnerships. With the establishment of dedicated organizations, environmental initiatives, and governance enhancements, we are now poised to pursue sustainability management at a global level.”
In a broader context, recent regulatory shifts in the United States could provide an indirect boost to Alteogen and its partners. The FDA announced plans to simplify biosimilar approvals starting October 1, 2026. These changes—allowing the skipping of costly Phase 3 trials if biological equivalence is proven, reducing comparative data requirements, and abolishing separate interchangeable biosimilar designations—are expected to help small and medium biotech firms like Alteogen’s partners enter the U.S. market faster. As Smedaily noted, this could accelerate the inflow of royalty revenues for platform companies such as Alteogen.
Meanwhile, institutional investors seem to be regaining some faith. On April 8, 2026, Alteogen was among the top 20 net purchases by institutional investors on KOSDAQ, with its stock price rising 5.79% compared to the previous day, according to Korea Economic Daily.
Alteogen’s journey is far from over. The company faces a crucial period where it must not only secure new contracts and resolve legal uncertainties but also demonstrate transparency and rebuild trust with its investors. If it can bridge the gap between promise and proof, this storm could mark just another chapter in its ongoing story of resilience and reinvention.